Landos Biopharma
Landos Biopharma Reports Third Quarter 2022 Results and Provides Business Update
- Form
- 8-K
- Filed
- Period
- Importance
- Major
- Accession
- 0000950170-22-024185
- Document
- 8-K
- Exhibit 99.1
- Press release
- Reports quarterly results (2.02)
Not explained yet; the original is on EDGAR.
Similar companies
Same SIC code (2834) and public float not reported.
